Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2010-022534-84-AT
EUCTR2010-022534-84-AT
Active, not recruiting
Not Applicable

A multi-center, open-label, single-arm study to evaluate hormone and lipid levels in male subjects with partial onset seizures after a switch of treatment from carbamazepine as adjunctive treatment to levetiracetam to lacosamide as adjunctive treatment to levetiracetam.

CB Pharma SA0 sites28 target enrollmentOctober 20, 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsEpilepsy: partial onset seizures.MedDRA version: 14.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
DrugsVimpat

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Epilepsy: partial onset seizures.
Sponsor
CB Pharma SA
Enrollment
28
Status
Active, not recruiting
Last Updated
12 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 20, 2011
End Date
TBD
Last Updated
12 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Male

Investigators

Sponsor
CB Pharma SA

Eligibility Criteria

Inclusion Criteria

  • •1\.An Independent Ethics Committee (IEC) approved written Informed Consent form is signed and dated by the subject or legal representative.
  • •2\.Subject/legal representative is considered reliable and capable of adhering to the protocol, visit schedule or medication intake according to the judgment of the investigator.
  • •3\.Subject is male and between 18 and 45 years of age, inclusive.
  • •4\.Subject has a diagnosis of epilepsy with partial\-onset seizures according to the International Classification of Epileptic Seizures (1981\) (See Section 15\.1\).
  • •5\.Subject is only taking LEV in combination with CBZ as adjunctive treatment for epilepsy.
  • •6\.Subject has been treated with CBZ for at least 12 months before study entry.
  • •7\.Subject has been maintained on a stable dose of CBZ and LEV during the 30 days before study entry.
  • •8\.The dose of CBZ at Visit 1 is \=600mg/day to \=1200mg/day.
  • •9\.The dose of LEV at Visit 1 is \=1000mg/day.
  • •10\. Subjects for whom a change from adjunctive treatment of CBZ and LEV to adjunctive

Exclusion Criteria

  • •Subjects are not permitted to enroll in the study if any of the following criteria are met:
  • •1\.Subject has previously participated in this study or subject has previously been assigned to treatment in a study of LCM.
  • •2\.Subject has participated in another study of an investigational medicinal product (IMP) or an experimental medical device within the last 30 days or is currently participating in another study of an IMP or a medical device.
  • •3\.Subject has a known hypersensitivity to any components of LCM tablets.
  • •4\.Subject has taken an AED other than CBZ and LEV within the last 30 days, excepting 1 time use of benzodiazepines as rescue medication (less than or equal to 3 doses within 24 hours).
  • •5\. Subject has taken lipid lowering agents within the last 30 days.
  • •6\. Subject has taken any medication known to affect endocrine function within the last 30 days, including exogenous hormones (eg, thyroid hormone, anabolic steroids, androgens, or glucocorticoids).
  • •7\.Subject has taken other enzyme inducers within the last 30 days (eg, St. John’s wort, rifampicin).
  • •8\.Subject is suffering from a known endocrine disorder where the condition or its treatment might influence SHBG levels, reproductive hormones, thyroid hormones, or serum lipid levels.
  • •9\.Subject has a medical condition that could reasonably be expected to interfere with drug absorption, distribution, metabolism, or excretion.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A multi-center, open-label, single-arm study to evaluate hormone and lipid levels in male subjects with partial onset seizures after a switch of treatment from carbamazepine as adjunctive treatment to levetiracetam to lacosamide as adjunctive treatment to levetiracetam.
EUCTR2010-022534-84-DECB Pharma SA28
Active, not recruiting
Phase 1
on-controlled, open-label study to evaluate tolerability, safety, and efficacy of MOB015B solution for external use in the treatment of mild to moderate fungal infection of the nail in subjects aged 6-17 yearsDistal Subungual OnychomycosisTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2022-001797-59-ITMoberg Pharma AB30
Active, not recruiting
Phase 1
on-controlled, open-label study to evaluate tolerability, safety, and efficacy of MOB015B solution for external use in the treatment of mild to moderate fungal infection of the nail in subjects aged 6-17 yearsDistal Subungual OnychomycosisMedDRA version: 20.0Level: SOCClassification code: 10021881Term: Infections and infestations Class: 1Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
CTIS2024-513214-34-00Moberg Pharma AB (publ)26
Active, not recruiting
Phase 1
on-controlled, open-label study to evaluate tolerability, safety, and efficacy of MOB015B solution for external use in the treatment of mild to moderate fungal infection of the nail in subjects aged 6-17 years
EUCTR2022-001797-59-DKMoberg Pharma AB (publ.)30
Active, not recruiting
Phase 1
on-controlled, open-label study to evaluate tolerability, safety, and efficacy of MOB015B solution for external use in the treatment of mild to moderate fungal infection of the nail in subjects aged 6-17 yearsDistal Subungual OnychomycosisMedDRA version: 20.0Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2022-001797-59-PLMoberg Pharma AB (publ.)30